Antiandrogens
Aspirin
Bromhexine
Budesonide
Cannabidiol
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Diet
Ensovibep
Exercise
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Melatonin
Metformin
Molnupiravir
Nigella Sativa
Nitazoxanide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Proxalutamide
Quercetin
Remdesivir
Sleep
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback Home
Home   COVID-19 treatment studies for Exercise  COVID-19 treatment studies for Exercise  C19 studies: Exercise  Exercise   Select treatmentSelect treatmentTreatmentsTreatments
Antiandrogens (meta) Lactoferrin (meta)
Aspirin (meta) Melatonin (meta)
Bamlaniv../e.. (meta) Metformin (meta)
Bebtelovimab (meta) Molnupiravir (meta)
Bromhexine (meta) N-acetylcys.. (meta)
Budesonide (meta) Nigella Sativa (meta)
Cannabidiol (meta) Nitazoxanide (meta)
Casirivimab/i.. (meta) Paxlovid (meta)
Colchicine (meta) Peg.. Lambda (meta)
Conv. Plasma (meta) Povidone-Iod.. (meta)
Curcumin (meta) Probiotics (meta)
Diet (meta) Proxalutamide (meta)
Ensitrelvir (meta) Quercetin (meta)
Ensovibep (meta) Remdesivir (meta)
Exercise (meta) Sleep (meta)
Famotidine (meta) Sotrovimab (meta)
Favipiravir (meta) Tixagev../c.. (meta)
Fluvoxamine (meta) Vitamin A (meta)
Hydroxychlor.. (meta) Vitamin C (meta)
Iota-carragee.. (meta) Vitamin D (meta)
Ivermectin (meta) Zinc (meta)

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent: 
0 0.5 1 1.5 2+ Case, >1/week vs. none 43% Improvement Relative Risk Case, 1-4/mon vs. none 62% c19early.com/ex Beydoun et al. Exercise for COVID-19 Prophylaxis Favors exercise Favors inactivity
Beydoun, 2,158 patient exercise study: 43% fewer cases [p=0.05] https://c19p.org/beydoun
copied to clipboard
Socio-demographic, lifestyle and health characteristics as predictors of self-reported Covid-19 history among older adults: 2006-2020 Health and Retirement Study
Beydoun et al., American Journal of Infection Control, doi:10.1016/j.ajic.2022.02.021
12 Mar 2022    Source   PDF   Share   Tweet
Retrospective 2,830 people in the USA, showing lower risk of COVID-19 with a history of moderate/vigorous exercise.
risk of case, 43.0% lower, OR 0.57, p = 0.05, high activity levels 1,710, low activity levels 448, adjusted per study, multivariable, >1/week vs. none, model 2, RR approximated with OR.
risk of case, 62.0% lower, OR 0.38, p = 0.010, high activity levels 672, low activity levels 448, adjusted per study, multivariable, 1-4/mon vs. none, model 2, RR approximated with OR.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Beydoun et al., 3/12/2022, retrospective, USA, North America, peer-reviewed, survey, 7 authors.
Contact: hind.a.baydoun.civ@mail.mil (corresponding author), baydounm@mail.nih.gov, sharminh6@gmail.com, balemu@email.wcu.edu, rana.gautam@ung.edu, jordanmnw@gmail.com, zondermana@mail.nih.gov.
All Studies   Meta Analysis
Please send us corrections, updates, or comments. Vaccines and treatments are both valuable and complementary. All practical, effective, and safe means should be used. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases mortality, morbidity, collateral damage, and the risk of endemic status. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit